ArticleThe British journal of dermatology2014
Patient satisfaction with treatments for moderate-to-severe plaque psoriasis in clinical practice.
Article in The British journal of dermatology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 95 citations in OpenAlex.
- Population-Pharmacokinetic Modeling of Tildrakizumab (MK-3222), an Anti-Interleukin-23-p19 Monoclonal Antibody, in Healthy Volunteers and Subjects with Psoriasis.Clinical pharmacokinetics · 2019Trial
- Tofacitinib for the treatment of moderate to severe chronic plaque psoriasis in Japanese patients: Subgroup analyses from a randomized, placebo-controlled phase 3 trial.The Journal of dermatology · 2017Trial
- Improvements in patient-reported outcomes in patients with psoriasis receiving etanercept plus topical therapies: results from REFINE.Journal of the European Academy of Dermatology and Venereology : JEADV · 2015Trial
- Autoimmune Type 1 Diabetes in the Era of Disease-Modifying Immune Therapy.Diabetes/metabolism research and reviews · 2025Review
- Treatment satisfaction among patients with psoriasis in Saudi Arabia.Dermatology reports · 2024Article
- Factors Associated with Treatment Satisfaction in Korean Patients with Psoriasis.Patient preference and adherence · 2024Article
- Disease severity, treatment patterns, and quality of life in patients with moderate-to-severe psoriasis routinely managed with systemic treatment: results of the CRYSTAL observational study in Central and Eastern European countries.Frontiers in immunology · 2024Observational
- Development and validation of a psoriasis treatment acceptability measure through group concept mapping.Health and quality of life outcomes · 2023Article
- Treatment satisfaction and response in patients with severe alopecia areata under treatment with diphenylcyclopropenone.Health science reports · 2022Article
- The Impact of Hypertension, Diabetes, Lipid Disorders, Overweight/Obesity and Nicotine Dependence on Health-Related Quality of Life and Psoriasis Severity in Psoriatic Patients Receiving Systemic Conventional and Biological Treatment.International journal of environmental research and public health · 2021Article
- Patient satisfaction with calcipotriol/betamethasone dipropionate cutaneous foam for the treatment of plaque psoriasis: The LION real-life multicenter prospective observational cohort study.Dermatologic therapy · 2021Observational
- Physician-patient alignment in satisfaction with psoriatic arthritis treatment in Latin America.Clinical rheumatology · 2020Article
- Efficacy of a Topical Formulation of Sodium Bicarbonate in Mild to Moderate Stable Plaque Psoriasis: a Randomized, Blinded, Intrapatient, Controlled Study.Dermatology and therapy · 2019Article
- Recommendations for Initiating Systemic Therapy in Patients with Psoriasis.The Journal of clinical and aesthetic dermatology · 2019Review
- Benefit-risk profile of tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: pooled analysis across six clinical trials.The British journal of dermatology · 2019Article
- Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis.Therapeutic advances in chronic disease · 2018Review
- Economic Impact of Above-Label Dosing with Etanercept, Adalimumab, or Ustekinumab in Patients with Psoriasis.Journal of managed care & specialty pharmacy · 2017Article
- National Psoriasis Foundation Priorities for Patient-Centered Research: Proceedings from the 2016 Conference.Journal of psoriasis and psoriatic arthritis · 2017Article
- The Challenge of Managing Psoriasis: Unmet Medical Needs and Stakeholder Perspectives.American health & drug benefits · 2016Review
- The MARCOPOLO Study of Ustekinumab Utilization and Efficacy in a Real-World Setting: Treatment of Patients with Plaque Psoriasis in Asia-Pacific Countries.Annals of dermatology · 2016Article
Corrections and comments
- Commented on by
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundTreatment satisfaction among patients with moderate-to-severe psoriasis has not been studied and compared across treatments using a validated instrument.
objectivesTo assess patient-reported satisfaction with systemic and phototherapy treatments for moderate-to-severe psoriasis in clinical practice and to correlate satisfaction with disease severity and quality-of-life measures.
methodsThis was a cross-sectional study of 1182 patients with moderate-to-severe psoriasis in the Dermatology Clinical Effectiveness Research Network in the U.S.A. Patients receiving either topical therapies only; monotherapy with oral systemic therapies, biologics or narrowband ultraviolet B phototherapy; or combination therapy with biologics and methotrexate completed the Treatment Satisfaction Questionnaire for Medication version II.
resultsMedian unadjusted overall satisfaction scores were highest for patients receiving biologic monotherapies, biologic-methotrexate combinations, or phototherapy (83.3); scores were lowest for those receiving topical therapies only or acitretin (66.7). In fully adjusted models, compared with patients receiving methotrexate monotherapy, those receiving adalimumab, etanercept, ustekinumab, phototherapy or adalimumab with methotrexate had significantly higher median overall satisfaction scores by 7.2-8.3 points, while those receiving topical therapies only had significantly lower overall satisfaction by 8.9 points. Adjusted convenience scores were lowest for patients receiving topical therapies only or infliximab. Modest but significant correlations were found between the overall satisfaction subscale and both the Psoriasis Area and Severity Index (ρ = -0.36, P < 0.001) and the Dermatology Life Quality Index (ρ = -0.47, P < 0.001).
conclusionsDiscernible differences were found in treatment satisfaction among therapies, particularly regarding treatment effectiveness and convenience. Further application of treatment satisfaction measures may inform treatment decisions and guideline development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.